Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) has announced it will host a live webcast and conference call on Tuesday, March 4, 2025, at 8:30 a.m. ET to review the company's fourth quarter and full year 2024 financial results and provide business updates.
The clinical-stage biotechnology company, which focuses on RNA medicines to transform human health, will make the webcast accessible through the "Investor Events" section of their website at https://ir.wavelifesciences.com/events-publications/events.
Analysts who wish to participate in the Q&A portion can join via an audio conferencing link that will provide dial-in information upon registration. An archived version of the webcast will be available on the company's website following the live event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, WVE declined 1.15%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company’s fourth quarter and full year 2024 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and Obesity, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
FAQ
When will Wave Life Sciences (WVE) release its Q4 and full year 2024 financial results?
How can investors access Wave Life Sciences' (WVE) Q4 2024 earnings call?
What will be discussed during Wave Life Sciences' (WVE) March 4, 2025 conference call?
Will Wave Life Sciences (WVE) provide a recording of their Q4 2024 earnings call?
